Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU)

Study of Circulating Tumoral DNA Evolution in Plasma in Choroidal Melanoma

Quantification and follow-up during 3 years of circulating tumoral DNA in patients with choroidal melanoma

This study is a prospective, open-labelled, monocentric trial. The aim is to observe, in patient with choroidal melanoma (any stage of the disease), the prevalence of the circulating tumor DNA at the diagnostic and its evolution during 3 years.

The patient will have a blood sample at the following times :

• T0: before treatment of the primary tumor.
• T1: 1 months after the end of the local treatment.
• T2: at 7 months.
• Tn: every 6 months up to 3 years.

Inclusion Criteria:

• Aged 18 years old or more.
• Patient with a recent choroidal melanoma before the start of the specific treatment.
• Patient able to stand a blood collection.
• Work-up for extension (CT).
• Patient explanation given and consent information signed or by legal representative

Exclusion Criteria:

• Patient without social protection / insurance.
• Person deprived of liberty or under guardianship.
• Inability to submit to medical monitoring of the trial for reasons of geography, social or psychological